Novocure (NVCR) Stock Forecast & Price Target

NovoCure is expected to see significant growth potential with its innovative TTFields devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers, as well as its pipeline products and technologies for various types of cancer. Its upcoming key catalysts, such as the TRIDENT study for newly diagnosed GBM, have the potential to extend therapy duration and integrate into standard care, while the KEYNOTE-D58 and PMA decisions for brain metastases represent incremental catalysts. However, without sustained patient growth or evidence of longer treatment duration, it is uncertain if this will translate into significant revenue acceleration or profitability in the near-to-medium term. The preliminary 4Q25 revenue of $174.4MM beat expectations, primarily driven by strong domestic net sales of Optune Gio and continued growth in active patients on TTFields globally. However, revenue contributions from new indications, such as NSCLC and MPM, continue to reflect limited traction, likely due to competition and short treatment durations. Upcoming milestones, such as the results from the Ph 2 PANOVA-4 study in metastatic pancreatic cancer and the Ph 3 TRIDENT study in newly diagnosed GBM, are expected to be key catalysts for the company's growth. However, the company remains cautious on the

NovoCure is facing significant challenges in its market, including growing competition in the solid tumor cancer space and potential delays in product development. Additionally, their valuation is based on a high multiple compared to their peers and is reliant on future sales and royalties from their GBM franchise. These factors, combined with the uncertainties around their pipeline and potential negative impact on its financials, make us maintain our negative outlook on the stock.